Hims & Hers Cuts Profit Forecast, Shares Decline
Shares of telehealth company Hims & Hers Health fell after the company lowered the upper end of its full-year adjusted EBITDA guidance. The decision was viewed as a negative signal in the markets, intensifying selling pressure from investors.
According to Bloomberg, the company revised its financial outlook, with the narrowing of operational profitability expectations drawing particular attention. The reduction in the upper limit of the adjusted EBITDA forecast points to challenges in meeting growth targets.
Hims & Hers had recently experienced growth amid rising demand for telehealth services. However, the downward revision of its profitability expectations suggests that factors such as cost pressures or intensifying competition may be having an impact.
The decline in the stock price reflects investor concerns about the company's short-term profitability outlook. Analysts are closely monitoring the implications of the revised guidance on the company's growth strategy.
This is not investment advice.
📊 HIMS — Piyasa Yorumu
▼ down · 65%The headline indicates that the company has lowered its profit forecast and that the stock has lost value, which is a negative signal in the short term. Although technical indicators are slightly positive (RSI around 60, MACD positive), the impact of the news may suppress momentum. The price is above the SMA20 and SMA50, but a fundamental negative such as a profit revision could make it difficult to test technical resistance levels. Selling pressure is likely within the next 1-3 days, but the decline is not expected to be severe as the overall trend remains upward. Investors may take time to price in the details of the news and the company's new guidance.
RSI 14
60.0
MACD
0.37
24h Δ
1.46%
Canlı Grafikler
🔗 İlgili haberler
⭐ 67 · 29.07
ABD FTC, Hims & Hers'ı Kullanıcı Sağlık Verilerini Meta ve Snap'e Göndermekle Suçluyor
⭐ 75 · 25.06
Hims obezite ilacı işine, işverenlerin kapsamı düşürmesiyle destek gelebilir
⭐ 63 · 02.06
Hims & Hers, Eucalyptus'u Satın Alarak Japonya Pazarına Girdi
⭐ 63 · 21.05
Hims & Hers, Kanada'da GLP-1 Piyasasına Giriyor, Hisse Değeri Artıyor
⭐ 63 · 21.05
Hims & Hers, Kanada'da Jenerik Semaglutidi Aylık 149 Dolara Sunuyor
⭐ 67 · 12.05
Hims & Hers Health Hisseleri Sert Düşüş Yaşadı
🧬 Buna benzer
⭐ 85
Lululemon hisseleri düştü: Beklenti düşüşü yeni CEO'nun zorluklarını gözler önüne serdi
⭐ 80
Boston Scientific Yıllık Tahmini Düşürdü, Hisseler Reset Sonrası Yükseldi
⭐ 65
ABD Borsaları Rekor Seviyede, Netflix Tahminleri Karşılayamadı
⭐ 80
Levi Strauss Premium Denim Talebiyle Beklentileri Yükseltti, Hisseler Geriledi
AI tarafından yeniden derlenmiştir. Yatırım tavsiyesi değildir.